Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112021 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00112021: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00112021 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00112021, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Interventions
- DRUG pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00112021 record still lists
NCT00112021 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).
The record links to 0 conditions, and to 1 intervention - of which pramlintide acetate is the first listed.
NCT00112021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00112021 about?
NCT00112021 is a clinical study titled "A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects". This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
What is the current status of trial NCT00112021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2005-05. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00112021?
The interventions under investigation include: pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00112021?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00112021's enrollment target sits among peer trials
400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia